Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimera outlines EU commercial strategy and raises $40m to market Iluvien

This article was originally published in Scrip

Executive Summary

Alimera Sciences will raise $40 million from the sale stock plus warrants to finance commercialization of Iluvien (fluocinolone acetonide) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) in Europe, where the company intends to focus its marketing efforts while US FDA approval remains elusive.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel